News Sentiment

RXRX sentiment intelligence

Recursion Pharmaceuticals Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 52 Balanced news tone 70 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 3.56 Week of 10 Jul 2026
Weighted tone 52/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

86/100 classification confidence.

Company focus 62

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend inactive

-6.3% over one week, +13.0% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

Why Recursion Pharmaceuticals (RXRX) Outpaced the Stock Market Today

Market Reaction

Price moving ahead of tone

62/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 86/100 classification
One-week reaction -6.3% Price reacting lower
Trend fit Trend inactive 13.0% over four weeks
Fair value -46.2% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 14
Neutral 48
Negative 8

Relevance

Why the article matched

Direct first
Direct company coverage 62
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 19
Market source 11
simplywall.st 7
TradingView 4
Quiver Quantitative 4
Sahm 3
Motley Fool 2
Stocktwits 1

Event Lens

What the news is about

Classified themes
Market update 51
Earnings 14
Balance sheet 3
Analyst action 2

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-60 of 70
Stock Titan Direct company coverage

Recursion (NASDAQ: RXRX) director Elaine Sun receives 88,424 restricted stock units

Recursion Pharmaceuticals (NASDAQ: RXRX) director Elaine Sun has been granted 88,424 restricted stock units (RSUs) as an equity award, with no cash cost, under the company’s Outside Director Compensation Policy. These RSUs will vest on the earlier of June 17, 2027, or the day bef

Tone
Neutral 50/100
Event
Balance sheet
Published
23 Jun 2026 01:39
Source
Stock Titan
Stock Titan Direct company coverage

Recursion (RXRX) director Zavain Dar granted 88,424 restricted stock units

Recursion Pharmaceuticals (RXRX) director Zavain Dar was granted 88,424 restricted stock units (RSUs) for board service. These RSUs, valued at $0.00 per share, will vest on the earlier of June 17, 2027, or the day before the 2027 annual stockholder meeting, contingent on continue

Tone
Neutral 50/100
Event
Market update
Published
22 Jun 2026 20:39
Source
Stock Titan
Stock Titan Direct company coverage

Recursion (NASDAQ: RXRX) director gets 88,424 restricted stock units

Recursion Pharmaceuticals (NASDAQ: RXRX) director Franziska Michor was granted 88,424 restricted stock units as compensation under the company's Outside Director Compensation Policy. These units were granted at $0.00 per share and will vest on June 17, 2027, or the day before the

Tone
Neutral 50/100
Event
Market update
Published
22 Jun 2026 20:39
Source
Stock Titan
Stock Titan Direct company coverage

Recursion (NASDAQ: RXRX) director Dean Y. Li granted 88,424 RSUs, updates holdings

Recursion (NASDAQ: RXRX) director Dean Y. Li was granted 88,424 restricted stock units (RSUs) as part of the company's Outside Director Compensation Policy. These RSUs, valued at $0.00 per share, are set to vest on June 17, 2027, or the day before the 2027 Annual Meeting of Stock

Tone
Neutral 50/100
Event
Market update
Published
22 Jun 2026 20:39
Source
Stock Titan
Stock Titan Direct company coverage

Recursion (RXRX) director receives 88,424 restricted stock units award

Recursion Pharmaceuticals (RXRX) director Blake Borgeson was granted 88,424 restricted stock units of Class A common stock under the company’s Outside Director Compensation Policy. These units will vest on the earlier of June 17, 2027, or the day before the 2027 annual stockholde

Tone
Neutral 50/100
Event
Market update
Published
22 Jun 2026 20:39
Source
Stock Titan
Quartr Direct company coverage

Recursion Pharmaceuticals (RXRX) Proxy filing Summary

Recursion Pharmaceuticals (RXRX) will hold its annual meeting virtually on June 17, 2026, where shareholders will vote on the election of two Class II directors, executive compensation, and auditor ratification. The company, a clinical-stage TechBio firm, uses AI for drug discove

Tone
Positive 63/100
Event
Market update
Published
20 Jun 2026 00:39
Source
Quartr
Stock Titan Direct company coverage

Recursion (NASDAQ: RXRX) investors back board nominees and PwC as 2026 auditor

Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) shareholders approved all management proposals at their 2026 annual meeting on June 17, 2026. Shareholders re-elected Class II directors Najat Khan, Ph.D., and Franziska Michor, Ph.D., and advisory approved executive compensation. Th

Tone
Positive 64/100
Event
Market update
Published
19 Jun 2026 00:39
Source
Stock Titan
Stock Titan Direct company coverage

RXRX (NASDAQ) proposed resale of multiple 40,000-share blocks between Mar–Jun 2026

RXRX (Recursion Pharmaceuticals, INC.) has filed a Form 144, indicating proposed resales of Class A founder shares. The filing details multiple 40,000-share blocks with potential trade dates spanning from March to June 2026, each with an associated dollar value. Fidelity Brokerag

Tone
Neutral 50/100
Event
Market update
Published
19 Jun 2026 00:09
Source
Stock Titan
Stock Titan Direct company coverage

Christopher C. Gibson sells six 40,000-share lots (RXRX) across Mar–Jun 2026

Christopher C. Gibson, an insider at Recursion Pharmaceuticals (RXRX), filed a Form 144 detailing six separate sales of 40,000 Class A shares each between March and June 2026. The filing also indicates scheduled restricted stock vesting events for Class A shares in 2025 and 2026.

Tone
Neutral 50/100
Event
Market update
Published
18 Jun 2026 20:09
Source
Stock Titan
Stock Titan Direct company coverage

RXRX (NASDAQ) affiliate files Form 144 to sell 3,963 Class A shares

An affiliate of Recursion Pharmaceuticals (RXRX) has filed a Form 144, indicating an intent to sell 3,963 Class A shares resulting from restricted stock vesting on June 18, 2026. This filing also discloses a prior sale of 4,386 Class A shares by Namandje Bumpus on June 3, 2026. T

Tone
Neutral 50/100
Event
Market update
Published
18 Jun 2026 13:40
Source
Stock Titan
Stock Titan Direct company coverage

Recursion (NASDAQ: RXRX) CFO covers taxes with 5,396 withheld shares

Recursion Pharmaceuticals' CFO, Ben R. Taylor, reported a tax-related disposition where 5,396 shares of Class A Common Stock were withheld to cover tax obligations stemming from restricted stock units. The shares were withheld at a price of $3.15 per share. Following this transac

Tone
Neutral 50/100
Event
Market update
Published
17 Jun 2026 21:10
Source
Stock Titan
Sahm Direct company coverage

Recursion Pharmaceuticals (RXRX) Stock Could Be 67% Overvalued After Pipeline Updates

Recursion Pharmaceuticals (RXRX) is gaining attention due to recent clinical updates and an upcoming presentation at the Goldman Sachs Global Healthcare Conference, leading to a recent share price increase. Despite this, some analyses suggest the stock is significantly overvalued

Tone
Negative 39/100
Event
Market update
Published
16 Jun 2026 12:40
Source
Sahm
Investing.com Direct company coverage

Recursion Pharmaceuticals CEO Najat Khan sells $84,459 in RXRX stock

Recursion Pharmaceuticals CEO Najat Khan sold 23,588 shares of RXRX stock totaling $84,459 on June 5, 2026, through a pre-planned trading arrangement. Despite this sale, Khan still holds over 2.1 million shares, and the company is considered undervalued by InvestingPro. The compa

Tone
Neutral 50/100
Event
Market update
Published
08 Jun 2026 08:10
Source
Investing.com
Investing.com South Africa Direct company coverage

Recursion Pharmaceuticals CEO Najat Khan sells $84,459 in RXRX stock By Investing.com

Najat Khan, CEO of Recursion Pharmaceuticals, sold 23,588 shares of RXRX stock for $84,459 on June 5, 2026, as part of a Rule 10b5-1 trading plan. Following the sale, Khan directly holds over 2.17 million shares, and the company has a market cap of $1.77 billion. The article also

Tone
Negative 40/100
Event
Market update
Published
06 Jun 2026 08:10
Source
Investing.com South Africa
Stock Titan Direct company coverage

Recursion Pharmaceuticals (RXRX) CEO sells 23,588 shares in planned Rule 10b5-1 trade

Recursion Pharmaceuticals CEO Najat Khan sold 23,588 shares of Class A Common Stock at a weighted average price of $3.5806 per share under a pre-arranged Rule 10b5-1 trading plan. After the sale, Khan still directly holds a significant 2,175,796 shares. This transaction, detailed

Tone
Negative 38/100
Event
Market update
Published
05 Jun 2026 20:39
Source
Stock Titan